司库奇尤单抗治疗活动性强直性脊柱炎两年持续改善:III期研究结果
MEASURE 2研究显示,活动性强直性脊柱炎患者随机接受司库奇尤单抗150mg、75mg或安慰剂,104周时ASAS20应答率均为71.5%,ASAS40均为47.5%,疗效持续且安全性与此前报告一致。
要点
- 司库奇尤单抗150mg和75mg组104周ASAS20应答率均为71.5%,ASAS40均为47.5%。
- 所有次要终点临床改善持续至104周。
- 严重感染发生率1.2/100患者年,未报告结核再激活或机会性感染。
核心结论
- 司库奇尤单抗治疗活动性强直性脊柱炎至104周可维持症状和体征改善,安全性与此前报告一致。
研究设计与样本
- III期MEASURE 2研究,219例活动性强直性脊柱炎患者随机接受皮下司库奇尤单抗150mg、75mg或安慰剂,评估至104周。
主要发现
- 104周时,司库奇尤单抗150mg和75mg组ASAS20应答率均为71.5%,ASAS40应答率均为47.5%。
- 所有次要终点(包括ASAS5/6、BASDAI、SF-36 PCS、ASAS部分缓解、EQ-5D、FACIT疲劳子量表)的临床改善持续至104周。
- 整个治疗期间(平均司库奇尤单抗暴露735.6天),严重感染和侵染、克罗恩病、恶性或未特指肿瘤、主要不良心脏事件的暴露调整发生率分别为1.2、0.7、0.5、0.7/100患者年。
- 未报告结核再激活、机会性感染或自杀意念病例。
关键数值与推荐
- 主要终点为第16周ASAS20应答率;104周ASAS20和ASAS40应答率均为71.5%和47.5%(两种剂量合并报告)。
- 二分类变量采用多重插补,连续变量采用混合效应模型重复测量。
临床怎么用
- 司库奇尤单抗150mg或75mg皮下注射可用于活动性强直性脊柱炎,疗效可维持至2年。
- 长期治疗中需关注严重感染、克罗恩病、肿瘤和主要不良心脏事件,发生率分别为1.2、0.7、0.5、0.7/100患者年。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Secukinumab improved the signs and symptoms of ankylosing spondylitis (AS) over 52 weeks in the phase III MEASURE 2 study. Here, we report longer-term (104 weeks) efficacy and safety results. METHODS: Patients with active AS were randomized to subcutaneous secukinumab 150 mg, 75 mg, or placebo at baseline; weeks 1, 2, and 3; and every 4 weeks from week 4. The primary end point was the Assessment of SpondyloArthritis international Society criteria for 20% improvement (ASAS20) response rate at week 16. Other end points included ASAS40, high-sensitivity C-reactive protein, ASAS5/6, Bath Ankylosing Spondylitis Disease Activity Index, Short Form 36 health survey physical component summary, ASAS partial remission, EuroQol 5-domain measure, and Functional Assessment of Chronic Illness Therapy fatigue subscale. End points were assessed through week 104, with multiple imputation for binary variables and a mixed-effects model repeated measures for continuous variables. RESULTS: Of 219 randomized patients, 60 of 72 (83.3%) and 57 of 73 (78.1%) patients completed 104 weeks of treatment with secukinumab 150 mg and 75 mg, respectively; ASAS20/ASAS40 response rates at week 104 were 71.5% and 47.5% with both secukinumab doses, respectively. Clinical improvements with secukinumab were sustained through week 104 across all secondary end points. Across the entire treatment period (mean secukinumab exposure 735.6 days), exposure-adjusted incidence rates for serious infections and infestations, Crohn's disease, malignant or unspecified tumors, and major adverse cardiac events with secukinumab were 1.2, 0.7, 0.5, and 0.7 per 100 patient-years, respectively. No cases of tuberculosis reactivation, opportunistic infections, or suicidal ideation were reported. CONCLUSION: Secukinumab provided sustained improvement through 2 years in the signs and symptoms of AS, with a safety profile consistent with previous reports.
引用
- Marzo-Ortega H, Sieper J, Kivitz A, et al. Secukinumab and Sustained Improvement in Signs and Symptoms of Patients With Active Ankylosing Spondylitis Through Two Years: Results From a Phase III Study. Arthritis Care Res (Hoboken). 2017. PMID: 28235249. doi:10.1002/acr.23233
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。